KOWA PHARMACEUTICAL EUROPE CO. LTD.

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +6.7%

  £18,144,000 → £19,367,000

• Cash

  +31.5%

  £10,758,000 → £14,149,000

• Net assets

  +24%

  £14,357,000 → £17,809,000

• Employees

  +5.9%

  17 → 18

• Operating profit

  +24.2%

  £3,525,000 → £4,377,000

• Profit before tax

  +50.3%

  £3,067,000 → £4,609,000

• Wages

  +2.5%

  £1,371,000 → £1,405,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

KPMG LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In addition to a profit for the year of £3.5m the company had net current assets of £17.8m as at 31 December 2024. These financial statements have been prepared on a going concern basis which the directors consider to be appropriate for the following reasons. The directors have prepared cash flow forecasts for a period of 12 months from the date of approval of these financial statements which indicate that, taking account of reasonably possible downsides including the ongoing political uncertainty from Europe, the Middle East and more recently the USA, due to challenges in supply chain, low/volatile exchange rates, the company will have sufficient funds to meet its liabilities as they fall due for that period. Consequently, the directors are confident that the company will have sufficient funds to continue to meet its liabilities as they fall due for at least 12 months from the date of approval of the financial statements and therefore have prepared the financial statements on a going concern basis.”

Significant events

• “The IOL business was sold on 30th September 2024 to a newly created sister company Kowa Medical Care Europe GmbH.”
• “From April 2024, purchase contracts denomination was changed from JPY to EUR, significantly reducing foreign exchange risk.”
• “The Company has entered into a new agreement to supply active ingredients Pitavastatin and Ezetimibe for product K-924 in the Middle East region, with the initial upfront license fee recognized in 2024.”
• “The Pitava trademark was approved in Greece in early 2025 resolving the trademark dispute.”
• “In early May 2025, the ultimate parent company requested the Company withdraw €11m cash from the Euro short term deposit account to loan this to another group company.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.